Kelly Joins Quintiles from Aetna

Kelly Joins Quintiles from Aetna

RESEARCH TRIANGLE PARK, NC – September 20, 2012 – Quintiles today announced Dr. Brian J. Kelly as the company's new president of Payer & Provider Solutions. This appointment is part of Quintiles' strategy to leverage its extensive therapeutic, scientific and analytics expertise to grow its presence in the promising hospitals and health plans markets. Kelly joined Quintiles in early September.

Kelly joins Quintiles from Aetna, where he was the head of Informatics, leading its efforts to measure the quality and affordability of healthcare. There, he also had previously served as the national medical director for the company's large commercial clients, where he provided clinical support for client sales and retention efforts, and helped to lead the development of its network and clinical programs.

"Brian has an impressive track record for understanding and using data to drive collaboration across the healthcare system to improve patient outcomes and reduce costs," said Tom Pike, chief executive officer, Quintiles. "We are delighted to have him join Quintiles and share his deep knowledge with our biopharma customers as they look for new models that drive greater predictability, and to expand our offerings to payers and providers."

Kelly said, "Payers and providers are exerting greater influence within the biopharma industry. Quintiles' customers recognize this shift and are eager to apply new methods to unlock the value of their drug therapies. I am excited about the opportunity to bring insight to help build upon Quintiles' capabilities in the areas of market access and payer and provider services, and to work directly with payers and providers to optimize their research and healthcare delivery capabilities."

Prior to Aetna, Kelly worked at Accenture, where he led its global electronic health record practice and consulted for numerous health plans, hospitals and governments, with a primary focus on using information technology to improve health care. Kelly is a former Navy neurologist and intensive care medicine specialist, retiring with the rank of captain in 2003. He spent most of his 20-year military career at the Navy's flagship hospital in Bethesda, Maryland, serving both as the head of the critical care medicine department and a staff neurologist. During this time, Kelly was recognized internationally for his expertise in the emerging field of neurocritical care and served as chairperson of the neurocritical care section of the American Academy of Neurology.

Kelly holds an M.D. from New York Medical College; an M.B.A. from George Washington University; an M.S. in bioengineering from Clemson University; and a B.A., in Russian, premed from the College of Holy Cross.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients' lives while demonstrating value to stakeholders. Visit for more information and for additional company news.


Greg Connors, Investor Relations
Office: +1 919 998 2000

Phil Bridges, Media Relations
Office: +1 919 998 1653

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.